Today it has been announced that thousands more vulnerable people will gain access to the UK’s second antiviral treatment, as we learn to live with Covid and offer long-term protection for the country’s most vulnerable people.
- As we learn to live with Covid, it is important that Britain continues to lead the way in using cutting-edge treatments which have already saved the lives of many of the country’s most vulnerable patients.
- That is why it has been decided to make available trialled access to the UK’s second antiviral treatment, Paxlovid, for vulnerable patients over 50 who are willing to participate in the vital study. Paxlovid reduced the risk of hospitalisation or death by 88 per cent in previous clinical trials and is already available directly through the NHS to highest-risk patients.
- Britain has procured more antivirals per head than any other country in Europe, as we know antivirals are key to offering early protections against the virus and helping the most vulnerable to live with Covid